### FORMATO EUROPEO PER IL CURRICULUM VITAE



### Personal information

First name / Surname

Address(es)

#### Roberto Salvioni

Work: Urology Unit - Fondazione IRCCS Istituto Nazionale dei Tumori di

Milano

Via G. Venezian 1 – 20133 Milano – ITALY.

Telephone(s)

s) Work: +390223902359

Fax

Work: +390223902708

E-mail

roberto.salvioni@istitutotumori.mi.it

Nationality

Italian

Date of birth

11 May 1952

Gender

Male

Work experience

Born in Milan on 11/05/1952. Degree in Medicine in 1978 with honors from the University of Milan with a thesis entitled: "Malignant tumors of the liver: our series." From 1977 he attended the Division of Surgical Oncology of the Institute for the Study and Treatment of Cancer in Milan. Specialization in 1982 with honors in Oncology at the University of Genoa, with a thesis on "Classification and Treatment of kidney cancer (particularly in relation to hormone receptors). Since 1984, deals with the status of research associate, of urological cancers and in particular those of the testis, at the Division of Urologic Oncology Institute for the Study and Treatment of Cancer in Milan. In 1988, with honors specialization in General Surgery at the University of Milan, with the thesis: "The treatment of cancer of the penis." Specializes in 1999 with honors in Urology at the University of Milan, with a thesis on "The conservative treatment of penile cancers. From 1990 to December 2006 Medical Director of the First Level Division of Urology at the National Institute for the Study and Treatment of Cancer in Milan. Since January 2007 Chair of Urologic Unit, IRCCS National Institute for the Study and Treatment of Cancer in Milan. It is author or coauthor of over 100 scientific publications in the field of urooncology. He has collaborated so far in national and international cooperative studies on testicular cancer. Since September 2005 he works as an international consultant with the Institut National du Cancer, Paris (INCA) for testicular cancer. He has performed as the first operator of more than 3000 surgical operations in highly specialized field uro-oncology.

October 2007 – December 2010

Dates

### Occupation or position held

Chair of Urolgiy Unit

# Main activities and responsibilities

Medical treatment of Germ-Cell tumors (including novel drugs and experimental therapies) and other genitourinary malignancies. Integration with surgery and high-dose therapies-transplantation in multimodal treatments for genitourinary neoplasms.

Chairman and co-chairman for the following clinical trials and initiatives:

- Prognostic factors for first salvage treatment of relapsed/refractory germ cell cancer: an International database.
- INT70/09: Phase 2 study with the multi-targeted tyrosine-kinase inhibitor Pazopanib (GW786034) for patients with relapsed or refractory urothelial cancer (NCT01031875).
- INT52/10: Phase II study of neoadjuvant cisplatin and gemcitabine plus sorafenib for transitional cell carcinoma of the bladder.
- INT38/10: Tandem high-dose chemotherapy (HDCT) with peripheral-blood stem-cell rescue for patients with metastatic germ-cell tumors failing first-line treatment (NCT01172912).
- Development of Institutional salvage strategies for patients with relapsed/refractory germ-cell cancer (including collaboration with Medical Oncology 3 - BMT Unit).
- Development of Institutional strategies for the treatment of locally advanced-metastatic urothelial cancers (including new targeted therapies).

Name and address of employer Urology Unit – Fondazione IRCCS Istituto Nazionale dei Tumori of Milan. Italy

# Personal skills and competences

Mother tongue

Italian

Other language

Self-assessment

European level (\*)

**English** 

| Understanding |                 |    |                 | Speaking |                    |    |                   | Writing |                 |  |
|---------------|-----------------|----|-----------------|----------|--------------------|----|-------------------|---------|-----------------|--|
| Listening     |                 |    | Reading         |          | Spoken interaction |    | Spoken production |         |                 |  |
| C2            | Proficient user | C2 | Proficient user | C2       | Proficient user    | C2 | Proficient user   | C2      | Proficient user |  |

<sup>(\*)</sup> Common European Framework of Reference for Languages

# Additional information

# INVITED SPEAKER AND ORAL PRESENTATIONS AT INTERNATIONAL & NATIONAL CONGRESSES:

#### **MEMBERSHIP IN PROFESSIONAL SOCIETIES:**

- Italian Germ cell cancer Group (IGG) from 2006 Vice President ,President from 2008
- European Association of Urology (EAU) from 2000
- Associazione Urologi Italiani: AuRo member of regional directive
- Società Italiana di Urologia :SIU from 2000
- Societa Italiana di Urologia Oncologica (SiURO) from 2012

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 196/03.

Milano, 07/08/2012

| Roberto Salvioni |  |  |  |  |  |
|------------------|--|--|--|--|--|
|                  |  |  |  |  |  |
|                  |  |  |  |  |  |
|                  |  |  |  |  |  |
| <br>             |  |  |  |  |  |